| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.DRUP.2009.04.001 |
| P8608 | Fatcat ID | release_of6nlfysejeg3phssauimmz6k4 |
| P932 | PMC publication ID | 4472331 |
| P698 | PubMed publication ID | 19467916 |
| P5875 | ResearchGate publication ID | 26239456 |
| P50 | author | Nathanael Gray | Q28112823 |
| P2093 | author name string | James D Griffin | |
| Qingsong Liu | |||
| Richard Stone | |||
| Ellen Weisberg | |||
| Rosemary Barrett | |||
| P2860 | cites work | The role of FLT3 in haematopoietic malignancies | Q24319174 |
| KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients | Q27653496 | ||
| Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies | Q27824769 | ||
| Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor | Q27824787 | ||
| A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome | Q27824793 | ||
| Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway | Q46944998 | ||
| PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial | Q47655625 | ||
| Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. | Q52575669 | ||
| A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia | Q58414438 | ||
| Internal tandem duplication of the flt3 gene found in acute myeloid leukemia | Q71841108 | ||
| Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia | Q73208706 | ||
| Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene | Q73674699 | ||
| Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia | Q73717211 | ||
| Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product | Q77299298 | ||
| Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia | Q80408098 | ||
| In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor | Q46832743 | ||
| Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene | Q46913925 | ||
| The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. | Q46932190 | ||
| Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia | Q27824808 | ||
| Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia | Q27851423 | ||
| Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor | Q27851455 | ||
| A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo | Q28217482 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Q29615030 | ||
| Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor | Q33241590 | ||
| Antitumor activity of sorafenib in FLT3-driven leukemic cells | Q33268279 | ||
| Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors | Q33373888 | ||
| Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia | Q33787254 | ||
| Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. | Q34139532 | ||
| Therapeutic options for acute myelogenous leukemia | Q34380840 | ||
| A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy | Q34549807 | ||
| Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens | Q34591403 | ||
| Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. | Q34765294 | ||
| ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia | Q35751114 | ||
| Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. | Q35849949 | ||
| Advances in understanding the biology and genetics of acute myelocytic leukemia | Q36061890 | ||
| Mammalian target of rapamycin as a therapeutic target in leukemia | Q36321019 | ||
| Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells | Q36508937 | ||
| Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo | Q36658028 | ||
| Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations | Q36742629 | ||
| Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs | Q36854122 | ||
| Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells | Q37003553 | ||
| Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications | Q37050507 | ||
| Implications of FLT3 mutations in the therapy of acute myeloid leukemia | Q37161270 | ||
| Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. | Q37234638 | ||
| Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. | Q37234641 | ||
| Small molecules ATP-competitive inhibitors of FLT3: a chemical overview | Q37347241 | ||
| Mechanisms of resistance to FLT3 inhibitors. | Q37375423 | ||
| A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease | Q39218023 | ||
| Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro | Q39889033 | ||
| A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. | Q39895136 | ||
| Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. | Q39895141 | ||
| Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia | Q39955358 | ||
| Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells | Q39960316 | ||
| Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. | Q39977455 | ||
| The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations. | Q40037030 | ||
| Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations | Q40077336 | ||
| A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations | Q40099203 | ||
| Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells | Q40109450 | ||
| 4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors | Q40111543 | ||
| BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. | Q40122807 | ||
| Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. | Q40165118 | ||
| AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells | Q40165143 | ||
| The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors | Q40182316 | ||
| The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling | Q40220256 | ||
| Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase | Q40275935 | ||
| Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations | Q40294499 | ||
| The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases | Q40303741 | ||
| Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain | Q40390558 | ||
| CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. | Q40480723 | ||
| Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). | Q40519489 | ||
| Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells | Q40526687 | ||
| In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects | Q40559231 | ||
| Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. | Q40659303 | ||
| Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. | Q40714821 | ||
| FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model | Q40760923 | ||
| Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor | Q40792187 | ||
| A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response | Q42192063 | ||
| Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia | Q42742064 | ||
| Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. | Q42815284 | ||
| Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). | Q42815993 | ||
| Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia | Q43199537 | ||
| A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations | Q43684737 | ||
| CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). | Q44068434 | ||
| SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase | Q44155418 | ||
| SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo | Q44280921 | ||
| Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification | Q44349388 | ||
| SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes | Q44370169 | ||
| Survival of acute myeloid leukemia cells requires PI3 kinase activation | Q44408364 | ||
| Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). | Q44483347 | ||
| An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. | Q44679244 | ||
| Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia | Q44906435 | ||
| Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. | Q44922362 | ||
| Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry | Q45029000 | ||
| Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Q45042550 | ||
| Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia | Q45063954 | ||
| Antileukemic activity of rapamycin in acute myeloid leukemia. | Q45154681 | ||
| PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways | Q45259661 | ||
| Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib | Q46124085 | ||
| Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase | Q46426194 | ||
| The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia | Q46538314 | ||
| CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia | Q46610628 | ||
| MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells | Q46659826 | ||
| Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication | Q46701464 | ||
| Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. | Q46788369 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug resistance | Q12147416 |
| P304 | page(s) | 81-89 | |
| P577 | publication date | 2009-05-20 | |
| P1433 | published in | Drug Resistance Updates | Q3040081 |
| P1476 | title | FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. | |
| P478 | volume | 12 |
| Q36408534 | A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. |
| Q41973517 | A potential therapeutic target for FLT3-ITD AML: PIM1 kinase |
| Q28076011 | Aberrant splicing and drug resistance in AML |
| Q41867996 | Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming |
| Q37978341 | Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? |
| Q38693701 | Andrographolide Suppresses MV4-11 Cell Proliferation through the Inhibition of FLT3 Signaling, Fatty Acid Synthesis and Cellular Iron Uptake |
| Q41592581 | Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase |
| Q41823976 | Cytokines secreted by bone marrow stromal cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis |
| Q38540961 | Discovery and characterization of novel mutant FLT3 kinase inhibitors |
| Q37771863 | Drug resistance in mutant FLT3-positive AML. |
| Q33903412 | E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia |
| Q38401664 | Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication |
| Q38435352 | Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets |
| Q35835233 | Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. |
| Q61799276 | FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells |
| Q33778374 | FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance |
| Q33704528 | FLT3mutation incidence and timing of origin in a population case series of pediatric leukemia |
| Q38803570 | Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies |
| Q37683815 | G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia |
| Q37789009 | Genetic instability in inherited and sporadic leukemias. |
| Q46406409 | Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression |
| Q64078533 | Homoharringtonine Combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia |
| Q42081830 | ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition |
| Q37676268 | In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development. |
| Q47716589 | Inhibition of USP10 induces degradation of oncogenic FLT3. |
| Q36682854 | Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target |
| Q39448700 | Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling. |
| Q91690031 | Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification |
| Q34412520 | MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1. |
| Q38671401 | Midostaurin for the treatment of acute myeloid leukemia |
| Q48212760 | Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside". |
| Q64118224 | Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation? |
| Q38180461 | Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells |
| Q59793137 | Novel Agents for Acute Myeloid Leukemia |
| Q35527456 | Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation |
| Q37236903 | Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia. |
| Q39398876 | PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS. |
| Q34640779 | Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia |
| Q33986236 | Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia |
| Q39381378 | Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation |
| Q36322776 | Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse |
| Q37043763 | Recent advances and novel agents for FLT3 mutated acute myeloid leukemia |
| Q38853220 | Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia |
| Q37642294 | Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q91591549 | STAT3β is a tumor suppressor in acute myeloid leukemia |
| Q35028968 | Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. |
| Q28486435 | Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells |
| Q36758390 | Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia |
| Q33683159 | Smac mimetics: implications for enhancement of targeted therapies in leukemia |
| Q35075792 | Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants |
| Q37401441 | Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors. |
| Q38011962 | Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia |
| Q28288602 | Targeting the dynamic HSP90 complex in cancer |
| Q39691687 | The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome |
| Q40356364 | The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation |
| Q35038725 | The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway. |
| Q37245131 | The role of the RAS pathway in iAMP21-ALL. |
| Q33745075 | Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. |
| Q92459714 | circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression |
Search more.